COVID-19 Saliva-based Screening Market

Global Market Study on COVID-19 Saliva-based Screening: Increasing Ageing Population Susceptible to COVID-19 to Complement Demand Growth Over Short Term

COVID-19 Saliva-based Screening Market Segmented By Saliva Collection Kits, Saliva Nucleic Acid Purification Kits, Saliva-based Detection Kits Product with Direct Sample to PCR, RT-qPCR, Lateral Flow Assays Technology

  • August-2021
  • PMRREP32712
  • 328 Pages
  • Healthcare
  • PPT, PDF, WORD, EXCEL

Market Snapshot

Global demand for COVID-19 saliva-based screening products is projected to observe a gradually declining trend of -3% through 2031, after an estimated market value of around US$ 2 Bn in 2021. As per Persistence Market Research’s projections, saliva-based detection kits hold a substantial share of over 83% in the overall market.

Find Out More about the Report Coverage

Companies

  • Thermo Fisher scientific
  • Qiagen
  • Hologic
  • Takara Bio Inc
  • Arcis Biotechnology Limited
  • GeneProof
  • Abacus ALS
  • Chai Inc.
  • Kolplast Group
  • Lucence Health INc
  • Vitagene
  • Therma Bright Inc
  • ACON Laboratories, Inc
  • TODA PHARMA
  • Norgen Biotek Corp.
  • Assure Tech. (Hangzhou) Co., Ltd
  • Beijing Hotgen Biotech Co., Ltd
  • Nantong Diagnos Biotechnology Co., Ltd
  • NeuMoDx Molecular, Inc.
  • KYODO INTERNATIONAL INC.
  • Canvax
  • Zymo Research Corporation.
  • Salimetrics
  • NEST Scientific USA
  • Miraclean Technology Co. Ltd
  • Mawi DNA Technologies
  • Cell Projects Ltd.

Key Insights Covered in COVID-19 Saliva-based Screening Industry Survey:

  • Market Estimates and Forecasts (2020-2031)
  • Key Drivers and Restraints Shaping Market Growth
  • Segment-wise, Country-wise, and Region-wise Analysis
  • Competition Mapping and Benchmarking
  • Market Share Analysis By Key Players
  • Key Product Innovations and Regulatory Climate
  • COVID-19 Impact on Demand for COVID-19 Saliva-based Screening and How to Navigate
  • Recommendation on Key Winning Strategies

Customize this Report

Explore Intelligence Tailored to Your Business Goals.

Sales Analysis of COVID-19 Saliva-based Screening Products from 2016 to 2020 Vs. Market Outlook for 2020 to 2031

The global COVID-19 saliva-based screening products market is set to contract at 3% CAGR from 2021-2031. The market trend for COVID-19 saliva-based screening products is expected to gradually decline over the years due to increasing focus on vaccination across countries, support from developing countries to supply vaccinations to underdeveloped countries, and the population attaining herd immunity.

Ever since the COVID-19 outbreak in 2019, incidence rate of the disease has been quite high. It has affected almost all countries across the globe. Since the recognition of COVID-19, there has been an exponential rise in the number of cases worldwide.

While developed regions such as the U.S. and Europe were greatly affected, developing countries such as India were no different. The major reason for the rapid spread was high transmissibility of the virus from person to person. This has increased demand for COVID-19 diagnostics across the globe.

Market Research Methodology - Perfected through Years of Diligence

A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.

Get actionable insights on Ship Repair And Maintenance Services Market

How is Increasing Ageing Population Susceptible to COVID-19 Impacting Demand for COVID-19 Saliva-based Screening?

The ageing population faces a significant risk of developing severe illness due to the physiological changes that come along with ageing and potential underlying health conditions. Poor health status, lowered organ function, weak immune function, increased probability of multiple underlying diseases, and poor attention to personal health can increase the susceptibility to various diseases in the older population.

Patient comorbidities such as hypertension, diabetes, and obesity steadily increase with age. This could be another logical explanation of higher COVID-19 mortality among older patients.

Additionally, other conditions such as cardiovascular disease and changes associated with immunosenescence may increase vulnerability to infection and the disproportionately high mortality owing to coronavirus infection in the geriatric population.

Therefore, increasing population aged above 65 years indicates that a higher population in this group is likely to be at risk of contracting the disease. Thus, the ageing population is more susceptible to viral infections, which is expected to boost demand for COVID-19 saliva-based screening.

According to a study, in 2020, in the population of 25 million men aged over 65 years, 23,487 fatality cases were reported, while 2,765 fatality cases were reported among 31 million women above 65 years in the U.S. It is believed that the new COVID-19 saliva test makes testing easier for all ages since the saliva-based method enables a simpler and quicker collection of samples.

Explore Persistence Market Research’s expertise in promulgation of the business !

What are the Key Opportunities on Offer for COVID-19 Saliva-based Screening Product Manufacturers?

The outbreak of the virus and its rapid spread has led countries to impose compulsory guidelines for COVID-19 diagnostics and other activities such as travelling. Many countries made it mandatory to issue a negative COVID-19 test to travel internationally as well as domestically.

Moreover, to break the chain, government guidelines have also included testing of individuals that may have come in contact with infected individuals. Rise in the number of tests due to government norms and guidelines represent considerable growth opportunities for COVID-19 saliva-based screening.

How is Dominance of Other COVID-19 Test Kits Restraining Demand for COVID-19 Saliva-based Screening Products?

Importance of saliva as a testing specimen is growing significantly owing to its convenience for both, self-collection and clinic use. However, the current market is still powered by other specimen testing kits that use samples apart from saliva, such as blood and nasopharyngeal swabs.

While many new players are expected to launch saliva-based kits, use of swabs for testing has not declined and remains a preferred option. This is an impacting factor for market growth. However, with rising adoption of saliva-based screening, saliva as a sample is expected to rule the specimen type.

Furthermore, along with prominent players in the market, even small companies are getting a stamp of FDA approvals for their saliva-based testing kits. This becomes a major restraint as many small companies are entering the market, and becomes a threat for key players in the market.

covid-19-saliva-based-screening-market

Country-wise Insights

What Makes the U.S. the Largest Market for COVID-19 Saliva-based Screening?

The U.S. dominates the North American region with a total market share of 91% in 2021, and is projected to continue experiencing low to moderate growth throughout the forecast period.

The FDA plays a crucial role in protecting the U.S. from threats of emerging infectious diseases, such as the outbreak of COVID-19. The FDA is dedicated to providing appropriate direction to support response efforts to the COVID-19 pandemic, and this is expected to positively affect market growth in the U.S.

For instance, the FDA has issued guidance to provide a policy and recommendations on evaluating the potential impact of emerging and future SARS-CoV-2 mutations on COVID-19 screening tests for the duration of the COVID-19 pandemic. This guidance has described a policy for test developers to consider the impact of emerging and future variants on their COVID-19 tests during development and post-authorization.

Moreover, increasing incidence rate of COVID-19 in the U.S. is also boosting demand for COVID-19 saliva-based screening. For instance, according to WHO, in the U.S., from January 3, 2020, to July 1, 2021, a total of 33,317,803 confirmed cases of COVID-19 were reported.

Why is Russia Considered a Lucrative Market for COVID-19 Saliva-based Screening in Europe?

Russia dominates the European market for COVID-19 saliva-based screening, with a share of 21%.

As of end-July, Russia reported a total of 839,981 COVID-19 cases. Between mid-March and mid-July 2020, the number of COVID-19 deaths exceeded 11,000, making Russia the fourth-most affected country after the U.S., Brazil, and India.

Thus, rising prevalence of COVID-19 in Russia is driving demand for Covid-19 screening.

How are International Partnerships to Combat the COVID-19 Pandemic Making India an Emerging Market for COVID-19 Saliva-based Screening?

India holds a 75% share in the South Asia market but is projected to decline at a CAGR of -2.8%.

The COVID-19 outbreak has affected many countries across South Asia. To combat the pandemic, many research institutes and companies are entering into strategic agreements to strengthen their diagnostics and therapeutics to develop effective diagnostic solutions.

For instance, in March 2020, the U.S. and India agreed on a long-standing productive partnership between research institutes and industries of both countries in the areas of diagnostics and therapeutics of the disease. Under the existing mutual partnership in the healthcare division, the National Institute of Allergy and Infectious Disease in the U.S. shared important reagents with the Translational Health Science Technology Institute in Gurgaon.

Such cooperation is expected to play a big role in developing new therapeutics in the COVID-19 diagnostics field that can offer lucrative opportunities for companies in the Indian market.

What is the Outlook for China Regarding COVID-19 Saliva-based Screening?

In 2020, China dominated the East Asia market with an 89% share, but is projected to observe a negative trend at a CAGR of -3.9% from 2021-2031

China has been observing increasing COVID-19 cases off late. COVID-19 saliva-based screening plays a significant role in the diagnosis and management of COVID-19 outbreaks.

Most companies in China are focusing on the development of COVID-19 saliva-based screening tests to deal with the outbreak of coronavirus. Thus, growing research on COVID-19 saliva-based screening is creating a lucrative market in China.

Category-wise Insights

Which COVID-19 Saliva-based Screening Product is Driving Market Growth?

By product, saliva-based detection kits will lead the market with a share of 82% over the forecast period.

COVID-19 has increased demand for saliva-based detection test kits. There is increase adoption of saliva collection kits amongst end-users. This inclination towards saliva-based tests can be due to escalating demand for home-based COVID-19 testing using saliva-based detection kits.

Why is RT-qPCR Technology Increasing Demand for COVID-19 Saliva-based Screening?

The RT-qPCR segment dominates the market with 49% revenue among other technologies. This trend is expected to continue during the study period.

High share of this segment is attributed to continued demand in areas such as gene expression analysis, genetic variation analysis, and genotyping, along with increasing focus on the development of RT-qPCR technology.

Why is COVID-19 Saliva-based Screening the Most Applicable as COVID-19 Diagnostics?

Based on application, COVID-19 diagnostics holds a large share of 63% in 2021. Rising prevalence of COVID-19, need for rapid diagnostics, and increasing demand for home-based COVID-19 testing are contributing to the growth of COVID-19 diagnostics.

Which End User is Most Preferred for COVID-19 Saliva-based Screening?

Based on end user, diagnostic laboratories lead the way with more than 27% market share. Diagnostic laboratories will provide lucrative opportunities for market growth owing to growing incidence of COVID-19 and increased virus mutation, which has led to an increase in the need for rapid detection with more accuracy.

What is the Impact of COVID-19 on the Industry?

The COVID-19 pandemic has given rise to various COVID-19 products and has created an unprecedented rise in demand for COVID-19 testing. This has resulted in many new manufacturers entering the market.

With rising COVID-19 cases across the globe occurring at different periods, demand for COVID-19 saliva-based screening has been quite consistent since 2020.

Moreover, with the occurrence of the second wave in countries in the last two quarters and the anticipated outbreak of the second and third waves across different countries, it can be predicted that demand for COVID-19 saliva-based screening will remain high.

Therefore, it can be rightly assumed that COVID-19 saliva-based screening will experience further growth during the forecast period due to the pandemic.

What is the Impact of Market Consolidation on the COVID-19 Saliva-based Screening Business Space?

Increasing COVID-19 saliva-based screening product launches, rising FDA approvals, and scientists focus on developing low-cost saliva-based COVID-19 tests are developing trends in the market.

Saliva-based COVID-19 tests enable comparably reliable but simpler and safer testing than other tests. As the COVID-19 virus continues to spread, many companies are offering advanced products in the market.

  • For instance, the saliva-based COVID-19 screening test developed by the Sys2diag laboratory (CNRS/Alcen) is easier and faster than an RT-PCR test performed using nasal swab samples and thus, can be used to accompaniment existing screening procedures.
  • EasyCov is based on the RT-LAMP technique on which amplifies viral RNA to detect its presence in a saliva sample. The 60 min initially required for heating before the results can be read were reduced to 40 min with no loss of performance.

The U.S. FDA approved the first home-collected saliva sample diagnostic kits for COVID-19 testing. Many companies are being granted approvals for their products.

  • For instance, Fluidigm received an FDA grant for its COVID-19 saliva test as an emergency authorization.

Competitive Landscape

Several leading players are focusing on advancements in in-vitro diagnostic procedures with rapid testing and expanding their product portfolios through the commercialization of products and product launches to increase their customer base and expand their sales footprint across the globe.

  • For instance, in March 2020, Abbott launched ID NOW, a molecular POCT for detecting novel coronavirus (COVID-19), authorized by the U.S. FDA-issued Emergency Use Authorization (EUA). It is small, lightweight (6.6 pounds) and portable (size of a small toaster), and uses molecular technology that delivers positive results in as little as five minutes and negative results in 13 min.
  • For instance, in April 2021, Chembio Diagnostics, Inc. launched an in-licensed rapid POCT for COVID-19 and got FDA Emergency Use Authorization-approval, this test is used in decentralized and traditional diagnostic laboratories. The product inventory was readily available to be shipped to customers across the U.S.

Report Scope as per COVID-19 Saliva-based Screening Industry Analysis

Attribute

Details

Forecast Period

2021-2031

Historical Data Available for

2016-2020

Market Analysis

US$ Mn for Value

Key Regions Covered

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Key Countries Covered

  • US
  • Canada
  • Brazil
  • Mexico
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Benelux
  • Russia
  • China
  • Japan
  • South Korea
  • India
  • Thailand
  • Indonesia
  • Malaysia
  • Singapore
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Turkey
  • Egypt
  • North Africa
  • South Africa
  • GCC Countries

Key Market Segments Covered

  • Product
  • Technology
  • Application
  • End User
  • Region

Key Companies Profiled

  • Thermo Fisher Scientific
  • Qiagen
  • Hologic
  • Takara Bio Inc
  • Arcis Biotechnology Limited
  • GeneProof
  • Abacus ALS
  • Chai Inc.
  • Kolplast Group
  • Lucence Health Inc
  • Vitagene
  • Therma Bright Inc
  • ACON Laboratories, Inc
  • TODA PHARMA
  • Norgen Biotek Corp.
  • Assure Tech. (Hangzhou) Co., Ltd
  • Nantong Diagnos Biotechnology Co., Ltd
  • NeuMoDx Molecular, Inc.
  • KYODO INTERNATIONAL INC.
  • Canvax
  • Zymo Research Corporation.
  • Salimetrics
  • NEST Scientific USA
  • Mawi DNA Technologies

Pricing

Available upon Request

Key Segments Covered in COVID-19 Saliva-based Screening Industry Research

By Product

  • Saliva Collection Kits
  • Saliva Nucleic Acid Purification Kits
  • Saliva-based Detection Kits
    • Rapid Test Kits
    • PCR-based Kits

By Technology

  • Direct Sample to PCR
  • RT-qPCR
  • Lateral Flow Assays

By Application

  • COVID-19 Research
  • COVID-19 Diagnostics

By End User

  • Diagnostic Laboratories
  • Hospitals & Clinics
  • Academic and Research Institutes
  • Biopharma Companies
  • Long Term Care Facilities
  • Home Care Settings
  • Others

FAQs Answered in Market Study

  • How much is the COVID-19 saliva-based screening market currently worth?

    The global COVID-19 saliva-based screening market is worth US$ 1.8 Bn at present, but is set to decline 1.2X over the next ten years.

  • What is the sales forecast for COVID-19 saliva-based screening through 2031?

    The market is expected to fall to US$ 1.5 Bn by the end of 2031, with sales revenue expected to decline at a CAGR of -3.0%.

  • What are the key trends shaping the COVID-19 saliva-based screening industry?

    Growing preference for point-of-care testing setting, demand for faster and effective COVID-19 saliva-based screening, and strategic acquisitions and new product launches are key trends being witnessed in this space.

  • Which are the top 5 countries driving demand for COVID-19 saliva-based screening?

    The U.S., Russia, U.K., China, and India are expected to drive demand for COVID-19 saliva-based screening.

  • Which countries are key producers of COVID-19 saliva-based screening products?

    The U.S., Russia, U.K., China, and India are major producers of COVID-19 saliva-based screening products.

  • What is the North American market outlook for COVID-19 saliva-based screening?

    North America is one of the key markets for COVID-19 saliva-based screening, with the U.S. expected to account for over 91% of the North American market.

  • At what percentage is demand for COVID-19 saliva-based screening expected to register growth in Europe?

    Demand for COVID-19 saliva-based screening in Europe is expected to register a CAGR of -9.5% during 2021-2025 and 2.3% during 2026-2031.

  • What is the market share held by the top 5 industry players?

    Cumulative market share of the top players constitutes around 25% of the overall market.

  • What are the key market statistics for Korea and Japan?

    Japan’s COVID-19 saliva-based screening market is expected to observe growth at -3.9% over the forecast period. South Korea holds a revenue share of 4% in the East Asia market.

Enquiry before Buying

  • Is the market research conducted by Persistence Market Research?

    Yes, the report filled with COVID-19 saliva-based screening market insights has been compiled by expert analysts of Persistence Market Research, through a combination of primary and secondary research. To know more about how the research was conducted, you can speak to a research analyst.

  • What research methodology is followed by Persistence Market Research?

    Persistence Market Research follows a methodology that encompasses the demand-side assessment and triangulates the same through a supply-side analysis. This methodology is based on the use of standard market structure, methods, and definitions.

  • Who are the respondents for primary research?

    Persistence Market Research speaks to stakeholders across the spectrum, including C-level executives, distributors, product manufacturers, and industry experts. For a full list of primary respondents, please reach out to us.

  • What are the sources of secondary research?

    Persistence Market Research conducts extensive secondary research through proprietary databases, paid databases, and information available in the public domain. We refer to industry associations, company press releases, annual reports, investor presentations, and research papers. More information about desk research is available upon request.

  • Is a sample of this report available for evaluation?

    Yes, you can request a sample, and it will be sent to you through email.

  • How can I buy this report?

    Persistence Market Research provides a secure online payment system to buy reports seamlessly. You can buy the report securely and safely.

Media Release

- FAQs -

The global COVID-19 saliva-based screening market is worth US$ 1.8 Bn at present, but is set to decline 1.2X over the next ten years.
The market is expected to fall to US$ 1.5 Bn by the end of 2031, with sales revenue expected to decline at a CAGR of -3.0%.
Growing preference for point-of-care testing setting, demand for faster and effective COVID-19 saliva-based screening, and strategic acquisitions and new product launches are key trends being witnessed in this space.
The U.S., Russia, U.K., China, and India are expected to drive demand for COVID-19 saliva-based screening.
The U.S., Russia, U.K., China, and India are major producers of COVID-19 saliva-based screening products.
North America is one of the key markets for COVID-19 saliva-based screening, with the U.S. expected to account for over 91% of the North American market.
Demand for COVID-19 saliva-based screening in Europe is expected to register a CAGR of -9.5% during 2021-2025 and 2.3% during 2026-2031.
Cumulative market share of the top players constitutes around 25% of the overall market.
Japan’s COVID-19 saliva-based screening market is expected to observe growth at -3.9% over the forecast period. South Korea holds a revenue share of 4% in the East Asia market.
The global COVID-19 saliva-based screening market is worth US$ 1.8 Bn at present, but is set to decline 1.2X over the next ten years.
The market is expected to fall to US$ 1.5 Bn by the end of 2031, with sales revenue expected to decline at a CAGR of -3.0%.
Growing preference for point-of-care testing setting, demand for faster and effective COVID-19 saliva-based screening, and strategic acquisitions and new product launches are key trends being witnessed in this space.
The U.S., Russia, U.K., China, and India are expected to drive demand for COVID-19 saliva-based screening.
The U.S., Russia, U.K., China, and India are major producers of COVID-19 saliva-based screening products.
North America is one of the key markets for COVID-19 saliva-based screening, with the U.S. expected to account for over 91% of the North American market.
Demand for COVID-19 saliva-based screening in Europe is expected to register a CAGR of -9.5% during 2021-2025 and 2.3% during 2026-2031.
Cumulative market share of the top players constitutes around 25% of the overall market.
Japan’s COVID-19 saliva-based screening market is expected to observe growth at -3.9% over the forecast period. South Korea holds a revenue share of 4% in the East Asia market.

Recommendations

Tissue Glue and Bio Adhesive Sealants Market

Global tissue glue and bio-adhesive sealants market was valued at US$ 1,156.3 Mn in 2015, it is anticipated to register a CAGR of 8.0% and is expected to reach US$ 2,281.2 Mn by 2024.

Rehabilitation Equipment Market

Global rehabilitation equipment market is forecasted to reach a figure of about US$ 13,400 Mn in 2022 and is poised to exhibit a robust CAGR in the period of assessment.

Medical And Industrial Gloves Market

Medical and Industrial Gloves Market at US$ 12,868.6 Mn by the end of 2026, exhibiting robust expansion at a CAGR of 7.9% over 2018–2026..

Acute Care Hospital Beds And Stretchers Market

The hospital beds product segment was the leading segment in the global acute care hospital beds and stretchers market with above 86.9% revenue share in 2017, and continue to dominate in 2026..

Our Clients

Our Clients